Signup for Email Updates
Country: 


Bedrocan Cannabis Corp. (Formerly POCML 2 Inc.) Completes Qualifying Transaction; Resulting Issuer Expected To Commence Trading August 25, 2014

POCML 2 closes QT with Bedrocan
Ticker Symbol: C:PCC

POCML 2 closes QT with Bedrocan

POCML 2 Inc (C:PCC)
Shares Issued 6,000,000
Last Close PCC.P 4/11/2014 $0.20
Thursday August 21 2014 - News Release

Mr. Marc Wayne reports

BEDROCAN CANNABIS CORP. (FORMERLY POCML 2 INC.) COMPLETES QUALIFYING TRANSACTION; RESULTING ISSUER EXPECTED TO COMMENCE TRADING AUGUST 25, 2014

POCML 2 Inc. has completed its qualifying transaction with Bedrocan Canada Inc., as previously announced in its press releases dated April 14 and May 15, 2014.

In connection with the Qualifying Transaction and prior to closing, the Corporation filed articles of amendment pursuant to which it (i) consolidated its common shares on the basis of one "new" common share (a "Post-Consolidation Share") for every two "old" common shares issued and outstanding (the "Consolidation"); and (ii) changed its name to "Bedrocan Cannabis Corp."A In addition, an aggregate of 13,500,000 subscription receipts of Bedrocan which were issued pursuant to a concurrent private placement completed by Bedrocan on May 15, 2014 (the "Concurrent Financing") were converted for no additional consideration into an aggregate of 13,500,000 common shares and 6,750,000 share purchase warrants of Bedrocan (the "Bedrocan Underlying Warrants") immediately pre-closing.A The Corporation then acquired all of the issued and outstanding securities of Bedrocan pursuant to a three cornered amalgamation in connection with which (i) Bedrocan amalgamated with a wholly-owned subsidiary of the Corporation; and (ii) the Corporation issued one Post-Consolidation Share to former Bedrocan shareholders in exchange for every common share of Bedrocan so acquired.A Pursuant to the Qualifying Transaction, the Corporation also issued (i) an aggregate of 2,000,000 stock options (the "Replacement Options") in consideration of the cancellation of existing stock options of Bedrocan; (ii) an aggregate of 6,750,000 share purchase warrants (the "Replacement Warrants") each exercisable at $1.20 until November 15, 2015 (subject to acceleration), in consideration of the cancellation of the Bedrocan Underlying Warrants; and (iii) an aggregate of 945,000 compensation options (the "Replacement Compensation Options") each exercisable to acquire one unit of the Corporation (a "Unit") at $0.85 until November 15, 2015 (subject to acceleration), in consideration of the cancellation of existing compensation options of Bedrocan issued in connection with the Concurrent Financing.A Each Unit consists of one Post-Consolidation Share and one-half of one Replacement Warrant (each whole such Replacement Warrant, an "Underlying Replacement Warrant").

Immediately following the closing, there are an aggregate of 67,500,000 Post-Consolidation Shares issued and outstanding, of which (i) 64,500,000 Post-Consolidation Shares are held by former shareholders of Bedrocan (inclusive of participants in the Concurrent Financing) and 3,000,000 Post-Consolidation Shares are held by existing shareholders of the Corporation.A In addition, immediately post-closing, the Corporation has reserved for issuance (i) an aggregate of 2,300,000 Post-Consolidation Shares issuable upon the exercise of stock options of the Corporation (inclusive of the Replacement Options) exercisable at prices ranging from $0.30 to $0.85 and bearing expiry dates ranging from November 20, 2014 to December 31, 2022 (Note: The Corporation intends to seek shareholder approval at its next annual meeting of certain amendments to its stock option plan to provide that the options granted thereunder may bear a term of up to 10 years from the date of grant); (ii) an aggregate of 11,000,000 Post-Consolidation Shares issuable upon the exercise of existing share purchase warrants of Bedrocan exercisable at $0.60 until the earlier of 18 months following the completion of a going public transaction by Bedrocan and April 4, 2019 (subject to acceleration); (iii) an aggregate of 80,000 Post-Consolidation Shares issuable upon the exercise of existing broker warrants of the Corporation exercisable at $0.30 until May 14, 2015; (iv) an aggregate of 945,000 Post-Consolidation Shares issuable upon the exercise of the Replacement Compensation Options; (v) an aggregate of 472,500 Post-Consolidation Shares issuable upon the exercise of the Underlying Replacement Warrants; and (vi) an aggregate of 6,750,000 Post-Consolidation Shares issuable upon the exercise of the Replacement Warrants. As described in the Corporation's filing statement dated August 8, 2014 available on SEDAR at www.sedar.com (the "Filing Statement"), certain of the Post-Consolidation Shares are subject to escrow requirements pursuant to applicable TSX Venture Exchange ("TSXV") policies. In addition to the securities subject to escrow described in the Filing Statement, 305,000 Post-Consolidation Shares, representing 0.45% of the Post-Consolidation Shares, held by the spouse of a principal of the Corporation, are subject to escrow. Such escrowed shareholder held 305,000 common shares of Bedrocan, representing 0.60% of the common shares of Bedrocan, immediately prior to the completion of the Qualifying Transaction.

In addition, following the closing, the Corporation granted an additional 861,000 stock options at an exercise price of $0.85 per share to certain executive officers, directors, employees and consultants of the Corporation, as previously described in the Filing Statement.

Also in connection with the Qualifying Transaction, the existing directors and officers of the Corporation resigned and the board of directors of the Corporation was reconstituted to be comprised of Messrs. Murray Goldman, Marc Wayne, Barry Fishman, Allan Mandelzys and Roderick Budd.A In addition, Mr. Murray Goldman was appointed as Chairman, Mr. Marc Wayne was appointed as Chief Executive Officer, Mr. Michael Singer was appointed as Chief Financial Officer, Mr. Hamish Sutherland was appointed as Chief Operating Officer and Mr. Tjalling Erkelens was appointed as Chief Production Officer of the Corporation.

Listing of the Post-Consolidation Shares is expected to commence on August 25, 2014 under the symbol "BED".

We seek Safe Harbor.

© 2014 Canjex Publishing Ltd.